0000313143-16-000117.txt : 20160414 0000313143-16-000117.hdr.sgml : 20160414 20160414163328 ACCESSION NUMBER: 0000313143-16-000117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160414 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160414 DATE AS OF CHANGE: 20160414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0328 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 161572102 BUSINESS ADDRESS: STREET 1: 400 WOOD RD CITY: BRAINTREE STATE: MA ZIP: 02184 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 8-K 1 april1420168-klindop.htm 8-K LINDOP 4-14-2016 8-K



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   April 14, 2016

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)

 
Massachusetts
 
1-14041
 
04-2882273
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

 
400 Wood Road, Braintree MA
 
02184
(Address of principal executive offices)
 
(Zip Code)
 Registrant’s telephone number, including area code  781-848-7100

(Former name or former address, if changed since last report.)

 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Retirement of Chief Financial Officer

On April 14, 2016, Haemonetics Corporation (the “Company”) announced that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development, will retire effective May 27, 2016. The Company will immediately begin a search for Mr. Lindop's successor.
A copy of the press release announcing Mr. Lindop’s retirement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Mr. Lindop’s decision to retire was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01. Financial Statements and Exhibits
(d) Exhibits
The following Exhibit is attached to this report:

Exhibit No.    Description

99.1
Press Release dated April 14, 2016 relating to retirement of Chief Financial Officer






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
HAEMONETICS CORPORATION
 
(Registrant)
 
 
 
 
 
 
Date: April 14, 2016
By
/s/ Sandra L. Jesse
 
 
Sandra L. Jesse
 
 
Executive Vice President, Chief Legal Officer








 EX-99.1 2 a4-14x2016haemoneticsprcli.htm EXHIBIT 99.1 Exhibit

Exhibit 99.1
News Release
FOR RELEASE:
 
INVESTOR CONTACT:
Date
April 14, 2016
 
Gerry Gould, VP-Investor Relations
Time
4:00pm
 
781 356-9402
 
 
 
gerry.gould@haemonetics.com
 
 
 
 
 
 
 
MEDIA CONTACT:
 
 
 
Sandra Jesse, Chief Legal Officer
 
 
 
781 356-9253
 
 
 
sandra.jesse@haemonetics.com
 
 
 
 
Haemonetics Announces CFO’s Retirement

Braintree, MA, April 14, 2016 - Haemonetics Corporation (NYSE: HAE) announced today that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development has announced his retirement from Haemonetics Corporation effective May 27, 2016. The Company announced it will immediately begin a search for Mr. Lindop’s successor.

Mr. Lindop joined the Company in 2007 and has led the Company's finance, investor relations and business development activities.

"Chris has made significant contributions to our global business and we wish him the best on his well-deserved retirement," said Ron Gelbman, Interim CEO.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at www.haemonetics.com.



1